Guidance, NICE advice and quality standards in development | Guidance

Showing 321 to 330 of 435

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	18 March 2026
Polycystic ovary syndrome: assessment and management	NICE guideline	3 November 2026
Prostate cancer: diagnosis and management (update)	NICE guideline	TBC
Psoriasis: assessment and management (CG153)	NICE guideline	TBC
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure	Diagnostics guidance	5 February 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance	7 April 2027
Rare diseases	Quality standard	27 February 2026
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017